期刊文献+

骨髓基质干细胞体内和体外分化为心肌细胞的条件 被引量:4

Condition of bone marrow mesenchymal stem cells differentiated into cardiomyocytes in vivo and in vitro
下载PDF
导出
摘要 目的:探讨5-氮胞苷和心肌内环境对骨髓基质干细胞(mesenchymalstemcells,MSCs)向心肌细胞转化的影响。方法:体外分离培养纯化MSCs,用Brdu标记MSCs,用不同浓度的5-氮胞苷诱导MSCs3周后,计算心肌细胞转化率。利用免疫组化方法测定诱导后MSCs中心肌特异性抗体(肌钙蛋白Ⅰ,肌凝蛋白重链)的存在。在体实验中,将体外标记的MSCs分为对照组,未诱导组,诱导组,移植给正常鼠,于移植后第1,2和4周取鼠心肌组织的HE病理切片镜下观察,使用免疫组化法检测Brdu阳性细胞中心肌特异性抗体的存在并观察MSCs向心肌细胞转化情况。结果:5-氮胞苷可以在体外诱导MSCs分化为心肌样细胞,而且在5μmol/L浓度的情况下,心肌样细胞转化率最高。同时,心肌内环境也可以诱导MSCs分化为心肌样细胞,而且避免了5-氮胞苷的副作用。结论:MSCs在5-氮胞苷和心肌内环境的作用下均可以分化为心肌样细胞,并具有心肌特异性蛋白结构,可以作为心肌细胞移植的理想种子来源。 AIM:To investigate the influence of 5-azacytidine(5-Aza) and myocardial internal environment on the differentiation of bone marrow mesenchymal stem cells(MSCs) into cardiomyocytes. METHODS:Bone marrow MSCs were isolated,cultured,purified and then labeled with Brdu in vitro.The ratio of MSCs differentiated into cardiomyocytes was calculated after induced with 5-Aza of different density for three weeks in vitro.The specific cardiomyocyte antibody(Troponin Ⅰand myosin heavy chain) in induced MSCs was testified by immunohistochemical method.In the experiment in vivo,the labeled MSCs were divided into three groups:control group,non-induction group and induction group.The labeled MSCs were transplanted into normal mice respectively,and then the HE pathological sections were observed under the microscope at 1,2 and 4 weeks after transplantation.The specific cardiomyocyte antibody in Brdu positive cells objectively was tested with immunohistochemical method,and the differentiation of MSCs into cardiomyocytes was observed. RESULTS:MSCs could be differentiated into cardiomyocytes by 5-Aza in vitro,and reached the highest differentiation ratio when 5-Aza at 5 μmol/L. Moreover,the myocardial internal environment could induce MSCs to differentiate into cardiomyocytes and avoid the side effects caused by 5-Aza. CONCLUSION:MSCs can differentiate into cardiomyocytes under the condition of 5-Aza and in the myocardial internal environment.The induced MSCs express the specific cardiomyocyte antibody,which can be as the better seed cells for the transplantation of cardiomyocytes.
出处 《中国临床康复》 CAS CSCD 北大核心 2005年第3期140-142,i002,共4页 Chinese Journal of Clinical Rehabilitation
基金 国家自然科学基金资助项目(30170369) 黑龙江省自然科学基金资助项目(9826)~~
  • 相关文献

参考文献12

  • 1张文元,杨亚冬,贺晨,陈勇.骨髓间充质干细胞的生物学特性及在组织修复中的应用[J].中国临床康复,2004,8(26):5614-5616. 被引量:7
  • 2鄂征.体外培养和分子生物学技术[M].北京:科学技术出版社,2000.197-8.
  • 3曹丰,牛丽丽,张鹏,陈琳,贾国良,裴雪涛.骨髓间充质干细胞异体移植修复慢性梗死心肌对左室功能的影响[J].中国临床康复,2004,8(24):5008-5010. 被引量:6
  • 4Makino S,Fukuda K,Miyoshi S,et al.Cardiomyocytes can be generated from marrow stromal cells in vitro.J Clin Invest 1999;103( 5): 697- 705.
  • 5Deryugina EI, Muller-Sieburg CE.Stromal cells in long-term cultures: keys to the elucidation of hematopoietic development? Crit Rev Immunol 1993;13( 2): 115- 50.
  • 6Pittenger MF,Mackay AM,Beck SC,et al.Multilineage potential of adult human mesenchymal stem cells.Science 1999; 284: 143- 7.
  • 7Wang JS,Shum-Tim D,Galipeau J,et al.Marrow stromal cells for cellular cardiomyoplasty:feasibility and potential clinical advantages.J Thorac Cardi ovasc Surg 2000;120:999- 1005.
  • 8Beltrami AP, Urbanek K, Kajstura J, et al.Evidence that human cardiac myocytes divide after myocardial infarction.N Engl J Med 2001;344( 23): 1750- 7.
  • 9Quaini F, Urbanek K, Beltrami AP, et al.Chimerism of the transplanted heart.N Engl J Med 2002;346( 1): 5- 15.
  • 10Toma C,Pittenger MF,Cahill KS,et al.Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart.Circulation 2002;105:93- 8.

二级参考文献43

  • 1Mahon NG, O' rorke C, Codd MB, et al. Hospital mortality of acute myocardial infarction in the thrombolytic era. Heart 1999; 81 (5):478 -82
  • 2Shake JG, Gruber PJ, Baumgartner WA, et al. Mesenchymal stem cell implantation in a swine myocardial infarct model: engraftment and functional effects. Ann Thorac Surg 2002;73(6): 1919 -25
  • 3Olivetti G, Melissari M, Capasso JM, et al. Cellular basis of chronic ventricular remodelling after myocardial infarction in rats. Cir Res 1991; 68 (6): 856-69
  • 4Wang JS, Shum-Tim D, Galipeau J, et al. Marrow stromal cells for cellular cardiomyoplasty: feasibility and potential clinical advantages. J Thorac Cardiovasc Surg 2000; 120(5): 999-1006
  • 5Li RK, Mickle DA, Weisel RD, et al. Optimal time for cardiomyocyte transplantation to maximize myocsrdial function after left ventricular injury Ann. Thorac Surg 2001; 72(6) : 1957-63
  • 6Deans RJ, Moseley AB. Mesenchymal stem cells: biology and potential clinical uses. Exp Hematol 2000; 28(8): 875-84
  • 7Saito T, Kuang JQ, Bittira B, et al. Xenotransplant cardiac chimera: immune tolerance of adult stem cells. Ann Thorac Surg 2002; 72 (1): 19-24
  • 8McIntosh K, Bartholomew A. Stromal cell modulation of the immune system. A potential role for mesenchymal stem cells. Graft 2000; 3:324-8
  • 9Orlic D, Kajstura J, Chimenti S, et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci USA 2001; 98(18): 10344-9
  • 10Tomita S, Mickle DA, Weisel RD, et al. Improved heart function with myogenesis and angiogenesis after autologous porcine bone marrow stromal cell transplantation. J Thorac Cardiovasc Surg 2002; 123(6): 1132-40

共引文献11

同被引文献50

引证文献4

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部